Global Human Albumin Market 2016-2020
About the Human Albumin Market
Albumin-based therapies such as Idelvion (CSL654 rIX-FP) by CSL Behring received marketing approval from the US FDA in March 2016 and from the EMA in May 2016. Apart from these, Albutropin (TV-1106) by Teva Pharmaceuticals, Ampion by Ampio Pharmaceuticals, and Albutein by Grifols (for Alzheimer's disease) are expected to enter the market during the forecast period.
The demand for albumin is high in APAC in countries like India and China. Still, the uptake of these therapeutics is less due to the lack of awareness about these products and their therapeutic uses. Thus, the awareness programs conducted by organizations such as PPTA, which includes International Plasma Awareness Week, to help increase the awareness about plasma donation and the different plasma protein therapies available, along with their potential uses, is expected to increase the uptake of these therapeutics in treating various conditions.
Technavio’s analysts forecast the global human albumin market to grow at a CAGR of 4.97% during the period 2016-2020.
Covered in this report
The report covers the present scenario and the growth prospects of the global human albumin market for 2016-2020. To calculate the market size, the report considers revenue generated from the sales of branded and generic albumin drugs used to treat infections, liver diseases, shock, during surgery, and severe burns. The report also considers the revenues to be generated from the sales of drugs that are expected to be launched in the market along with the decline in revenues from the genericization of the marketed drugs during the forecast period. The market is divided into the following segments based on geography:
Technavio Announces the Publication of its Research Report – Global Human Albumin Market 2016-2020
Technavio recognizes the following companies as the key players in the global human albumin market: CSL Behring, Grifols, Baxalta, Octapharma, and Kedrion.
Other Prominent Vendors in the market are: AADi, Ablynx, Albumedix, Ampio Pharmaceuticals, Azaya Therapeutics, Beijing Tiantan, Biotest, Bristol-Myers Squibb, Celgene, ConjuChem, GSK, Hebei Changshan Biochem Pharma, HiMedia Laboratories, Hualan Biological Engineering, InVittria, MedxBio, Merck, Mitsubishi Tanabe Pharma, NantBioScience, Novo Nordisk, Novozymes, Shanghai RAAS Blood Products, Sucampo Pharmaceuticals, Teva Pharmaceuticals, Thermo Fisher Scientific, Tianjin SinoBiotech & Beijing Bio-Fortune, Ventria Bioscience, and Yoshitomi Pharmaceutical.
Commenting on the report, an analyst from Technavio’s team said: “A trend helping to propel market growth is the rise in non-therapeutic applications. Non-therapeutic applications of albumin are on a rise. Research is yet to evaluate the applications of albumin as an excipient for commercial use. Some areas where albumin can be employed are as a drug-formulating agent, an ingredient in vaccines and sealant in surgeries, and to coat medical devices and equipment. Though the current supply of albumin for non-therapeutic purposes is low, the high interest shown by the research institutes and pharmaceutical and biopharmaceutical companies in investigating the potential non-therapeutic uses of albumin is expected to drive the market.”
According to the report, a key driver is the high demand for human albumin in China. China is the largest market for albumin products. Albumin is being used as a volume replacement therapy and for treating kidney diseases, cirrhosis, and cancer. But the demand for plasma products, primarily albumin and immunoglobulins, is outstripping the supply. This is because of the stringent regulations imposed on the supply of raw materials and ban in the import of plasma products. Because of the increased demand for albumin products, the ban on import of plasma products did not include albumin
Further, the report states that one challenge that could curtail market growth is the spread of pathogenic contaminants.
CSL Behring, Grifols, Baxalta, Octapharma, Kedrion, AADi, Ablynx, Albumedix, Ampio Pharmaceuticals, Azaya Therapeutics, Beijing Tiantan, Biotest, Bristol-Myers Squibb, Celgene, ConjuChem, GSK, Hebei Changshan Biochem Pharma, HiMedia Laboratories, Hualan Biological Engineering, InVittria, MedxBio, Merck, Mitsubishi Tanabe Pharma, NantBioScience, Novo Nordisk, Novozymes, Shanghai RAAS Blood Products, Sucampo Pharmaceuticals, Teva Pharmaceuticals, Thermo Fisher Scientific, Tianjin SinoBiotech & Beijing Bio-Fortune, Ventria Bioscience, Yoshitomi Pharmaceutical.
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook